-
Mashup Score: 0Article - 6 month(s) ago
IntroductionHIGHLIGHTSChronic immune and inflammatory diseases carry a level of risk for the development of lymphoma that is correlated with the severity of the disease.Primary and exclusive involvement of the sternum is a rare presentation of lymphoma but needs to be taken into account in any patient with chronic inflammatory or rheumatic disease.The radiological, histological, and clinical…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Article - 7 month(s) ago
INTRODUCTIONThe most common extranodal site of NHL is in the stomach, which represents 30%–40% of all extranodal lymphomas and 55%–65% of all gastrointestinal lymphomas.[1] Primary gastric lymphoma (PGL) is a rare lymphoma and diffuse large B-cell lymphoma (DLBCL) variant accounts for approximately 59% of cases across all subgroups.[2] While the annual incidence is 5–7/100,000 people, age is an…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breast implant-associated #lymphomas have caught clinicians' attention due to their unique characteristics. Among these, breast implant-associated Epstein-Barr virus-positive #DLBCL has emerged as a new lymphoproliferative entity. https://t.co/1l2DZXg1jf https://t.co/yEv3azjjGK
-
-
Mashup Score: 0Human Kidney-on-a-Chip Advances Cancer Drug Testing : Oncology Times - 7 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA approved several T-cell bispecific antibodies for the treatment of #leukemias, #lymphomas, and #myelomas. These antibody drugs label tumor cells with one of their ends and attract immune cells with another end to kill tumor cells. https://t.co/6fPAEyghqK https://t.co/zLMeAlNd2X
-
-
Mashup Score: 0
By Dibash Kumar Das, PhDBreast implant-associated lymphomas have caught the attention of clinicians due to their rarity and unique characteristics. Among these, breast implant-associated Epstein-Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL) has emerged as a new lymphoproliferative entity, recently classified as fibrin-associated large B-cell lymphoma (FA-LBCLs) by the World…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breast implant-associated #lymphomas have caught clinicians' attention due to their unique characteristics. Breast implant-associated fibrin-associated #DLBCL shows EBV positivity and exhibits a favorable prognosis with surgical management. https://t.co/DvCKRn92R5 https://t.co/ByNpkqUBBr
-
-
Mashup Score: 1Express Delivery of Next-Generation CAR T Cells with Preserved Naive and Stemness Phenotypes for the Treatment of Aggressive Lymphomas - 8 month(s) ago
Summary:. In this issue of Cancer Discovery, Dickinson and colleagues present clinical data from a first-in-human study of YTB323, a novel autologous CD19-directed chimeric antigen receptor T-cell therapy generated on the T-Charge platform with preserved naive state and stemness phenotypes. Treatment with YTB323 achieved high overall response rates, durable complete remissions, and good overall safety. Their cell doses are up to 25-fold lower than with tisagenlecleucel.See related article by Dickinson et al., p. 1982 (10).
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In the Spotlight: Express delivery of next-generation #CARTcells with preserved naïve and stemness phenotypes for the treatment of aggressive #lymphomas, by @michaelwangmd. https://t.co/v1fAJUWMB2 @MDAndersonNews https://t.co/yeRJ7vf9C0
-
-
Mashup Score: 0How Can We Improve Patient Access to Immunotherapy? : Oncology Times - 8 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"#Immunotherapies represent a massive paradigmatic change in #oncology. The first therapeutic that demonstrated the potential of immunotherapy was rituximab in patients with aggressive B-cell #lymphomas," noted Joseph Alvarnas, MD at @cityofhope. https://t.co/lpFu4ITcNP https://t.co/cByiycgeuu
-
-
Mashup Score: 1Oral Azacitidine Plus CHOP Shows Efficacy in Treatment-Naïve PTCL | ASH Clinical News | American Society of Hematology - 9 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Peripheral T-cell lymphomas (PTCL) are a relatively diverse mix of more than 30 subtypes of aggressiv e non-Hodgkin lymphomas (NHL) that typically have a poor prognosis when treated with conventional chemotherapy. Approximately 5% to 10% of all NHLs diagnosed in Western countries are a form of PTCL. The most frequently prescribed initial therapy for patients with PTCL is cyclophosphamide, doxorubicin, vincristine,
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Recent study findings published in @BloodJournal have indicated that the combination of oral #azacitidine plus CHOP as induction treatment induced high response rates among patients with peripheral T-cell #lymphomas https://t.co/hoLdoQR7W2
-
-
Mashup Score: 2
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR-T cells are now standard of care in a number of different therapeutic areas, including #lymphomas and #leukemias. Patrick Reville, MD, MPH, at @MDAndersonNews, is exploring ways to make them effective for more patients: https://t.co/WTEFbivUnh @patrickreville #CancerResearch https://t.co/EyaoOlZEHw
-
-
Mashup Score: 4
Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, says our Dr. Sattva Neelapu. Data from the ZUMA-1 trial suggests axi-cel could be an important option for a subset of patients with B cell #lymphomas. https://t.co/HRAwFtSF3r @AJMC #EndCancer
-
-
Mashup Score: 1Welcome - 11 month(s) ago
SpeakerJason Westin, MD, MS, FACPDirector, Lymphoma Clinical ResearchSection Chief, Aggressive Lymphoma Department of Lymphoma & Myeloma The University of Texas at MD Anderson Cancer Center Houston, TX
Source: na.eventscloud.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join our free #webcast: Spotlight on Aggressive Non-Hodgkin #Lymphomas on 6/7 at 2pm ET with Jason Westin, MD of @MDAndersonNews 👉 https://t.co/R4tF7jTDVt https://t.co/2FBF6YQ1gt
-
#Primarybonelymphoma is a rare entity that constitutes less than 1% of all non-Hodgkin #lymphomas and 3–5% of malignant #bonetumors. Chronic immune and #inflammatorydiseases carry risk for development of malignancies correlated with the disease severity. https://t.co/Qe3eY0zNTB https://t.co/eMlnZrbAOc